Download PDF
Thromb Haemost 2009; 102(06): 1285-1287
DOI: 10.1160/TH09-04-0248
Letters to the Editor
Schattauer GmbH

Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired α2-antiplasmin deficiency associated with AL amyloidosis

Giuseppe Colucci
1   Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
,
Lorenzo Alberio
1   Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
,
Maximilian Jahns
1   Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
,
Peter Keller
1   Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
,
Simon Steiner
1   Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
,
Ilka Rüsges-Wolter
1   Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
,
Bernhard Lämmle
1   Department of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital and University of Bern, Bern, Switzerland
› Author Affiliations
Further Information

Publication History

Received: 20 April 2009

Accepted after major revision: 13 September 2009

Publication Date:
28 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Mumford AD, O'Donnell J, Gillmore JD. et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000; 110: 454-460.
    CrossrefPubMedGoogle Scholar
  • 2 Gamba G, Montani N, Anesi E. et al. Clotting alterations in primary systemic amyloidosis. Haematologica 2000; 85: 289-292.
    PubMedGoogle Scholar
  • 3 Zangari M, Elice F, Fink L. et al. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost 2007; 33: 339-349.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Taylor Jr. FB, Toh CH, Hoots WK. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Dalton SO, Johansen C, Mellemkjaer L. et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64.
    CrossrefPubMedGoogle Scholar
  • 6 Meyer K, Williams EC. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis. Am J Med 1985; 79: 394-396.
    CrossrefPubMedGoogle Scholar
  • 7 Takahashi H, Koike T, Yoshida N. et al. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol 1986; 23: 153-166.
    CrossrefPubMedGoogle Scholar
  • 8 Liebman HA, Carfagno MK, Weitz IC. et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol 1992; 98: 534-541.
    CrossrefPubMedGoogle Scholar
  • 9 Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003; 89: 409-419.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Takahashi T, Suzukawa M, Akiyama M, et al. Systemic AL amyloidosis with disseminated intravascular coagulation associated with hyperfibrinolysis. Int J Hematol 2008; 87: 371-374.
    CrossrefPubMedGoogle Scholar